T-Cure BioScience, Inc. products
Technology
T-Cure - Isolation of Optimal Reverse Immunology Generated TCR (iSORT) Platform Technology
Our exclusive iSORT (Isolation of Optimal Reverse Immunology Generated TCR) platform is able to isolate TCRs against unique selected tumor-associated intracellular and extracellular antigens and neoantigens in the context of an HLA molecule, allowing us to focus on specific cancers and patient populations based on their genetic makeups. Using this technology, we are able to isolate TCR candidates capable of targeting antigens presented by both class I and class II HLA molecules.
T-Cure - Receptor Therapy T Cell
T cell engineering with TCRs is a growing area of immuno-oncology with recent breakthroughs in clinical settings. The T-Cure approach involves identifying and isolating a high avidity TCR which specifically recognizes an intracellular or cell-surface target in solid tumors. This TCR is then typically introduced into a viral vector that can deliver the TCR into the patients’ own T cells in an ex vivo setting. After successful genetic modification of the T cells in this way, T cells are re-introduced into the patient, and render effective killing of tumor cells in vivo.